Chemistry:S-309309
From HandWiki
S-309309 is an experimental MGAT2 inhibitor developed as an anti-obesity drug by the Japanese company Shionogi.[1][2] Phase II trial results are expected in late 2023.[3]
References
- ↑ "S-309309: a novel selective inhibitor of MGAT2 that exert potent anti-obesity effect in DIO mice.". Obesity 30: 277–278. November 2022.
- ↑ "MGAT2 Inhibition Activates NTS Neurons, Leading to Appetite Suppression and Beneficial Effects.". Obesity 30: 278–279. November 2022.
- ↑ "Obesity: Six trials to watch over the next 12 months". Clinical Trials Arena. 30 June 2023. https://www.clinicaltrialsarena.com/features/obesity-trials-to-watch/?cf-view.
 |  |
